SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a coope...
SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I...
SHENZHEN, China, Jan. 24, 2022 /PRNewswire/ -- Demonstrating innovation leadership on a global leve...
SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global ...
SHENZHEN, China, Aug. 10, 2021 /PRNewswire/ -- ImmVira announced that it has initiated its lead onc...
SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ -- ImmVira announced that as a global first, its lead on...
SHENZHEN, China, July 18, 2021 /PRNewswire/ -- On July 18, 2021, ImmVira inaugurated a pilot-scale ...
SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical T...
SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from its clinical Phase ...